Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study
Authors
Keywords
-
Journal
RMD Open
Volume 9, Issue 1, Pages e002850
Publisher
BMJ
Online
2023-02-22
DOI
10.1136/rmdopen-2022-002850
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort
- (2022) Elisabetta Zanatta et al. RHEUMATOLOGY
- Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
- (2022) Yannick Allanore et al. ANNALS OF THE RHEUMATIC DISEASES
- POS0063 PROGRESSIVE INTERSTITIAL LUNG DISEASE IS FREQUENT ALSO IN LATE DISEASE STAGES IN SYSTEMIC SCLEROSIS PATIENTS FROM EUSTAR
- (2022) A. M. Hoffmann-Vold et al. ANNALS OF THE RHEUMATIC DISEASES
- Integrating new therapies for systemic sclerosis-associated lung fibrosis in clinical practice
- (2021) Dinesh Khanna et al. Lancet Respiratory Medicine
- SYSTEMIC SCLEROSIS‐ASSOCIATED INTERSTITIAL LUNG DISEASE: How to incorporate two Food and Drug Administration‐approved therapies in clinical practice
- (2021) Dinesh Khanna et al. Arthritis & Rheumatology
- Predictors of progression in systemic sclerosis patients with interstitial lung disease
- (2020) Oliver Distler et al. EUROPEAN RESPIRATORY JOURNAL
- Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study
- (2020) Corrado Campochiaro et al. RHEUMATOLOGY
- Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
- (2020) Anna-Maria Hoffmann-Vold et al. ANNALS OF THE RHEUMATIC DISEASES
- Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Dinesh Khanna et al. Lancet Respiratory Medicine
- Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study
- (2019) Muriel Elhai et al. ANNALS OF THE RHEUMATIC DISEASES
- Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
- (2019) Oliver Distler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort
- (2019) Anna-Maria Hoffmann-Vold et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Aetiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease
- (2019) Dinesh Khanna et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Systemic sclerosis
- (2017) Christopher P Denton et al. LANCET
- Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis
- (2017) Nicole S. Goh et al. Arthritis & Rheumatology
- Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) -- Report from OMERACT CTD-ILD Working Group
- (2015) D. Khanna et al. JOURNAL OF RHEUMATOLOGY
- Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
- (2014) Suzana Jordan et al. ANNALS OF THE RHEUMATIC DISEASES
- 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
- (2013) Frank van den Hoogen et al. ANNALS OF THE RHEUMATIC DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation